Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.83 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.76 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853688 | 0.91 | ADORA2A (0.85) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| Zm-241385 SCHEMBL194966 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL7834626 | 0.90 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL9325947 | 0.86 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL9326085 | 0.85 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL9583202 | 0.85 | ADORA2A (0.81) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL9583900 | 0.85 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| [3H]-Zm-241385 SCHEMBL29443965 | 0.84 | ADORA2A (0.87) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL9329035 | 0.84 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 | |
| SCHEMBL29853732 | 0.84 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1949903-B1 | SELECTIVE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO BIOMEDICINA CIMA SL (ES) | 2012-04-18 | — | — | EP | disclosed |
| US-8012973-B2 | Compounds for the treatment of auricular fibrillation | PROYECTO DE BIOMEDICINA CIMA S.L. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-8012973-B2 | Compounds for the treatment of auricular fibrillation | PROYECTO DE BIOMEDICINA CIMA S.L. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-20090312332-A1 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-12-17 | — | — | US | disclosed |
| US-20090312332-A1 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-12-17 | — | — | US | disclosed |
| EP-1949903-A2 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | Proyecto de Biomedicina Cima, S.L. (ES) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007045705-A2 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2007-04-26 | — | — | WO | disclosed |
| US-5246932-A | Adenosine antagonist such as vasodilation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-09-21 | — | — | US | disclosed |
| EP-0515108-A2 | Azolo (1,3,5) triazines as adenosine antagonists | ZENECA LIMITED (GB) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312332-A1 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.